Exelixis: Zanzalintinib as a Major Hope in Cancer Therapies Ahead of FDA Approval
Reading Time: 3 minutes
Business Model: Exelixis focuses on targeted cancer therapies with kinase inhibitors. The main product, Cabometyx, is marketed both directly and through partners and primarily treats kidney, liver, and thyroid cancer. Clinical Progress: Recent data from the Phase 3 CABINET study demonstrate a risk reduction of disease progression by up to 74% in neuroendocrine tumors. Strong Quarterly Numbers: In the first quarter of 2026, the company exceeded analyst expectations with revenues of $610.8 million and earnings per share of $0.87, giving a...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
